An open-label, controlled, randomized, Phase 3 trial evaluating 12-month kidney function in highly sensitized (cPRA >= 99.9%) kidney transplant patients with positive crossmatch against a deceased donor, comparing desensitization using imlifidase wit

Protocol No

SURG-HANSA-CONFIDES

Phase

III

Summary

This project is being done to demonstrate the efficacy and safety of Imlifidase, a new medication, in the management of highly sensitized kidney transplant patients.

Description

Renal Function in Highly Sensitized Patients 1 Year After Desensitization With Imlifidase Prior to DD Kidney Tx (ConfIdeS)

Participating Institutions

Froedtert Hospital

Status

OPEN TO ACCRUAL

An open-label, controlled, randomized, Phase 3 trial evaluating 12-month kidney function in highly sensitized (cPRA >= 99.9%) kidney transplant patients with positive crossmatch against a deceased donor, comparing desensitization using imlifidase with standard of care